Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea

Phase 2

Completed

• Conditions: Pneumonia; Meningitis; Otitis Media
• Interventions: Biological: Pneumococcal 7 valent conjugate vaccine (Prevenar®)

• Registration Number: NCT00219401
• Lead Sponsor: Papua New Guinea Institute of Medical Research

Brief Summary

The National Health Plan 2001-2010 calls for investigation of the feasibility of pneumococcal vaccines for Papau New Guinea. The Papua New Guinea (PNG) Institute of Medical Research, the Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia will collaborate to examine very closely the safety of neonatal vaccination, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries.

Detailed Description

In order to obtain the earliest possible protection against invasive pneumococcal disease, achieve optimal coverage and reduce burden of early carriage, neonatal pneumococcal conjugate vaccine (PCV) immunization needs to be considered. This study in the PNG highlands will enrol 312 infants at birth, who will be randomised to receive PCV either at 1-2-3 months (infant schedule according to PNG national EPI schedule) or 0-1-2 months of age (neonatal schedule) or receive only routine immunizations (controls). Blood samples will be taken at birth-2-3-4 months of age, pre- and post-pneumococcal polysaccharide booster (23vPPV) at 9-10 months of age (to assess immune memory) and at 18 months at study completion. Carriage will be assessed weekly for the first month of life and at regular intervals thereafter. There will be ongoing surveillance for respiratory and other diseases throughout the study. In addition to serotype-specific IgG, we will examine IgG avidity, IgG subclasses, mucosal IgA and T-cell cytokine responses to PCV and pneumococcal protein antigens. To ensure immunological safety, particularly for neonatal PCV, immune responses to concomitant vaccines and viral and environmental antigens will also be examined as well as overall T-cell maturation.

Study Timeline

• Study Start: 2005-05
• Study First Submitted: 2005-09-15
• Study First Submitted QC: 2005-09-16
• Study First Posted: 2005-09-22
• Primary Completion: 2009-05
• Study Completion: 2010-05
• Status Verified: 2011-07
• Last Update Submitted: 2011-07-10
• Last Update Posted: 2011-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 318

Inclusion Criteria

New born babies with birth weight >2000 g (2 kgs) and parents giving consent

Read More

Exclusion Criteria

1. Acute neonatal infection;
2. Severe congenital abnormality;
3. Children of mothers known to be HIV positive will be excluded;
4. Serious asphyxia at birth;
5. Intended migration in the next 2 years;
6. Parents withdraw consent;

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Neonatal 7vPCV	Pneumococcal 7 valent conjugate vaccine (Prevenar®)	Receive study vaccine (Prevnar) at birth, 1 and 2 months
Infant 7vPCV	Pneumococcal 7 valent conjugate vaccine (Prevenar®)	Receive the study vaccine (Prevnar) at 1, 2 and 3 months
Control	Pneumococcal 7 valent conjugate vaccine (Prevenar®)	Do not receive study vaccine (Prevnar)

Primary Outcome Measures

Name	Time	Method
Immunogenicity and Safety	5 yrs	Serum PCV serotype-specific IgG antibody at 2, 4 and 9 mths. Mucosal PCV serotype-specific IgG antibody at 1, 3, 4 and 9 mths. PCV-induced T-cell memory (against vaccine protein carrier) at 3 and 9 mths. Local and systemic reactogenicity 48-96 hrs after vaccination. Monitoring of serious adverse events during 18 mth follow-up. T-cell development to bystander antigens at 3 and 9 mths.

Secondary Outcome Measures

Name	Time	Method
Immunogenicity	5 years	Serum PCV and non-PCV serotype specific IgG antibody at 10 mths, after 23vPPV vaccination at 9 mths
Pneumococcal-specific acquired immunity	5 years	Assessment of cellular immune responses to pneumococcal protein antigens at 9 and 18 months of age.

Trial Locations

Locations (1)

Papua New Guinea Institute of Medical Research; 🇵🇬 Goroka, EHP, Papua New Guinea